

**ASX/Media Release**  
**28<sup>th</sup> November 2014**

## **Results of Annual General Meeting**

**Sydney, 28<sup>th</sup> November, 2014: OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to announce all of the resolutions were passed**

We advise that:

a) The following resolutions were passed on a show of hands at the Annual General Meeting of OncoSil Medical Limited on Friday 28 November 2014.

Ordinary Business

### **Resolution 1 – Adoption of Remuneration Report**

To consider and, if thought fit, to pass, with or without amendment, the following resolution as a non-binding resolution:

“That, for the purpose of Section 250R(2) of the Corporations Act and for all other purposes, the Company adopts the Remuneration Report as set out in the Director’s Report in the Annual Report for the year ended 30 June 2014”.

### **Resolution 2 –Re-election of Martin Rogers**

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution:

“To re-elect Martin Rogers who retires by rotation in accordance with Listing rule 14.4 and Rule 13.2 of the Company’s Constitution and being eligible, offers himself for re-election as a Director.”

### **Resolution 3 - Approval of Issue of Loan Shares to Roger Aston**

To consider and if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution:

“That for the purposes of ASX Listing Rule 10.14 and for all other purposes, Shareholders approve the issue of a total of 2,000,000 Loan Shares to Dr. Roger Aston pursuant to the Employee Share Plan subject to the vesting conditions and otherwise on the terms and conditions outlined in the Explanatory Memorandum which accompanies this Notice of Meeting.”

#### **Resolution 4 - Approval of Issue of Issue of Shares to Derwent Executive**

To consider and if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution:

"That pursuant to ASX Listing Rule 7.1 and for all other purposes, Shareholders approve the issue of that many fully paid ordinary shares in the capital of the Company at the market price (as described in the accompanying Explanatory Memorandum) which in aggregate have a value of \$20,833.33 to Derwent Executive, the material terms of which are stated in the Explanatory Memorandum which accompanies this Notice of Meeting."

#### **Resolution 5 - Approval of Increased Placement Capacity**

To consider and if thought fit, to pass, with or without amendment, the following resolution as a special resolution:

"That pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the increase in the capacity of the Company to issue equity securities up to 10% of the issued capital of the Company (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions stated in the Explanatory Memorandum which accompanies this Notice of Meeting."

#### **Resolution 6 – Amendments to the Constitution**


To consider and, if thought fit, to pass, with or without amendment, the following resolution as an special resolution:

"That pursuant to section 136(2) of the Corporations Act and for all other purposes, the Shareholders of the Company approve the amendment of the Company Constitution as detailed in Schedule 2 to the Explanatory Memorandum accompanying this Notice of Meeting."

b) A summary of valid and eligible proxies received for the above meeting was as follows:

	Discretion	For	Against	Abstain
Resolution 1 Adoption of Remuneration Report	-	38,917,925	50,000	1,398,657
Resolution 2 Re-election of Martin Rogers	-	38,967,925	-	1,398,657
Resolution 3 Approval of Issue of Loan Shares to Roger Aston	-	38,917,925	50,000	1,398,657
Resolution 4 Approval of Issue of Issue of Shares to Derwent Executive	-	38,917,925	1,448,657	-
Resolution 5 Approval of Increased Placement Capacity	-	38,891,425	76,500	1,398,657
Resolution 6 Amendments to the Constitution	-	38,891,425	76,500	1,398,657

Yours faithfully  
OncoSil Medical Limited



**Peter Casey**  
Company Secretary

**About OncoSil Medical Ltd**

OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian biotechnology company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical's lead product is OncoSil™ with the first target indication being pancreatic cancer. OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumours outside of pancreatic cancer. FDA and EMA approval for pancreatic cancer is the core focus of OncoSil Medical.

**Pancreatic Cancer**

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2010 280,000 people globally were diagnosed with pancreatic cancer including 43,140 Americans, 70,000 Europeans and 2,546 in Australia. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The world-wide market for pancreatic drugs is projected by Global Industry Analysis to exceed US\$1.2bn by 2015.